US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Clinuvel Pharmaceuticals Ltd.

6.16

-0.6100-9.01%

Post-market: 6.160.00000.00%19:33 EDT

Volume:51.28K

Turnover:323.77K

Market Cap:310.64M

PE:14.35

High:6.56

Open:6.56

Low:6.12

Close:6.77

52wk High:8.92

52wk Low:5.98

Shares:50.43M

Float Shares:43.88M

Volume Ratio:3.51

T/O Rate:0.12%

Dividend:0.03

Dividend Rate:0.56%

EPS(TTM):0.4293

EPS(LYR):0.4707

ROE:13.21%

ROA:8.94%

PB:1.59

PE(LYR):13.09

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Clinuvel Pharmaceuticals Ltd.

Exchange:

NASDAQ

Establishment Date:

1999

Employees:

16

Office Location:

535 Bourke Street,Level 22,Melbourne,Victoria,Australia

Website:

http://www.clinuvel.com

Zip Code:

3000

Phone:

Fax:

61 3 9660 4999

Introduction:

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Directors

Name

Position

Guy van Dievoet

Non-Executive Director

Jeffrey Rosenfeld

Chair of the Board and Non-Executive Director

Karen Agersborg

Non-Executive Director

Matthew Pringle

Non-Executive Director

Pearl Grimes

Non-Executive Director

Susan Smith

Non-Executive Director

Shareholders

Name

Position

Philippe Wolgen

Chief Executive Officer and Managing Director

Lachlan Hay

Chief Operating Officer

Peter Vaughan

Chief Financial Officer

Dennis Wright

Chief Scientific Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/CUVL/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUVL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUVL\",,,,,undefined,":{"symbol":"CUVL","market":"US","secType":"STK","nameCN":"Clinuvel Pharmaceuticals Ltd.","latestPrice":6.16,"timestamp":1787947200000,"preClose":6.77,"halted":0,"volume":51280,"hourTrading":{"tag":"盘后","latestPrice":6.16,"preClose":6.16,"latestTime":"19:33 EDT","volume":36,"amount":221.46,"timestamp":1787960001769,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.09010339734121114,"floatShares":43878300,"shares":50427898,"eps":0.429335,"marketStatus":"Market Closed","change":-0.61,"latestTime":"08-28 16:00:00 EDT","open":6.56,"high":6.56,"low":6.12,"amount":323771.4076,"amplitude":0.064993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.429335,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"NASDAQ","adjPreClose":6.77,"dividendRate":0.005552,"preHourTrading":{"tag":"盘前","latestPrice":6.5,"preClose":6.77,"latestTime":"09:22 EDT","volume":4649,"amount":29882.2866445,"timestamp":1787923337414,"change":-0.27,"changeRate":-0.039882,"amplitude":0.041359},"postHourTrading":{"tag":"盘后","latestPrice":6.16,"preClose":6.16,"latestTime":"19:33 EDT","volume":36,"amount":221.46,"timestamp":1787960001769,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.50785982578455},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUVL\",,,,,undefined,":{"symbol":"CUVL","floatShares":43878300,"roa":"8.94%","roe":"13.21%","lyrEps":0.470726,"volumeRatio":3.50785982578455,"shares":50427898,"dividePrice":0.0342,"high":6.56,"amplitude":0.064993,"preClose":6.77,"low":6.12,"week52Low":5.98,"pbRate":"1.59","psRate":"4.61","week52High":8.92,"institutionHeld":0,"latestPrice":6.16,"eps":0.429335,"divideRate":0.005552,"volume":51280,"delay":0,"ttmEps":0.429335,"open":6.56,"prevYearClose":8.48,"prevWeekClose":7.8,"prevMonthClose":6.49,"prevQuarterClose":7.3,"fiveDayClose":7.8,"twentyDayClose":6.49,"sixtyDayClose":6.4,"dividendPayoutRate":0.055654438728341596,"dividendFrequency":"A","dividendGrowthYears":0,"dividendGrowthRate":-0.12779744805932258,"fiveYearAvgDividendRate":0.004014656862745098},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUVL\",params:#limit:5,,,undefined,":[{"date":"2026-09-08","symbol":"CUVL","amount":0.03582,"announcedDate":"2026-08-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-08","defaultRemindTime":1788874200000,"name":"Clinuvel Pharmaceuticals Ltd.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-28","payableDate":"2026-09-08","currency":"USD","dateTimestamp":1788840000000,"payDate":"2026-09-28"},{"date":"2026-08-27","symbol":"CUVL","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787817600000,"name":null,"time":"Pre-MKt","dateTimestamp":1787803200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUVL\",market:\"US\",,,undefined,":[{"executeDate":"2026-09-08","recordDate":"2026-09-08","paymentDate":"2026-09-28","value":0.03582,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CUVL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.2857,"hold":0.4286,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CUVL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CUVL","date":"2026-08-28","current":14.34777,"percent":0,"low":12.593289,"twenty":14.434144,"median":15.047836,"eighty":16.017964,"high":16.876512,"avg":15.116566,"sd":0.897212,"marketCap":307239459.07},"quantilePoints":[{"date":"2026-07-24","current":15.59024,"twenty":15.398074,"median":15.574742,"eighty":15.64603,"marketCap":353645627.74},{"date":"2026-07-31","current":14.040514,"twenty":14.675902,"median":15.311289,"eighty":15.580941,"marketCap":320255681.34},{"date":"2026-08-07","current":14.62941,"twenty":14.316365,"median":14.745639,"eighty":15.481759,"marketCap":334861674.87},{"date":"2026-08-14","current":14.79988,"twenty":14.434144,"median":14.861869,"eighty":15.354681,"marketCap":340007360.21},{"date":"2026-08-21","current":16.148141,"twenty":14.496133,"median":14.978098,"eighty":15.70182,"marketCap":374125095.76},{"date":"2026-08-28","current":12.593289,"twenty":14.434144,"median":15.047836,"eighty":16.017964,"marketCap":307239459.07}],"updateTime":1788123281518},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":6117181,"yearFounded":1999,"employeeNum":16,"address":"535 Bourke Street,Level 22,Melbourne,Victoria,Australia","zipCode":"3000","officePhone":"61 3 9660 4900","officeFax":"61 3 9660 4999","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://www.clinuvel.com","stockEarnings":[{"period":"1week","weight":-0.2103},{"period":"1month","weight":-0.0974},{"period":"3month","weight":-0.0772},{"period":"6month","weight":-0.1852},{"period":"1year","weight":-0.2651},{"period":"ytd","weight":-0.2736}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.016564},{"month":2,"riseRate":0.25,"avgChangeRate":-0.088904},{"month":3,"riseRate":0.375,"avgChangeRate":0.036975},{"month":4,"riseRate":0.625,"avgChangeRate":0.007121},{"month":5,"riseRate":0.555556,"avgChangeRate":0.057074},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013615},{"month":7,"riseRate":0.555556,"avgChangeRate":0.025547},{"month":8,"riseRate":0.555556,"avgChangeRate":0.022668},{"month":9,"riseRate":0.5,"avgChangeRate":0.03444},{"month":10,"riseRate":0.5,"avgChangeRate":-0.018995},{"month":11,"riseRate":0.5,"avgChangeRate":-0.022089},{"month":12,"riseRate":0.625,"avgChangeRate":0.039793}],"exchange":"NASDAQ","name":"Clinuvel Pharmaceuticals Ltd.","nameEN":"Clinuvel Pharmaceuticals Ltd.","securityTypeName":"DR","adrRate":"1:1"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CUVL\",market:\"US\",,,undefined,":{"directors":[{"name":"Guy van Dievoet","position":"Non-Executive Director"},{"name":"Jeffrey Rosenfeld","position":"Chair of the Board and Non-Executive Director"},{"name":"Karen Agersborg","position":"Non-Executive Director"},{"name":"Matthew Pringle","position":"Non-Executive Director"},{"name":"Pearl Grimes","position":"Non-Executive Director"},{"name":"Susan Smith","position":"Non-Executive Director"}],"executives":[{"name":"Philippe Wolgen","position":"Chief Executive Officer and Managing Director"},{"name":"Lachlan Hay","position":"Chief Operating Officer"},{"name":"Peter Vaughan","position":"Chief Financial Officer"},{"name":"Dennis Wright","position":"Chief Scientific Officer"}]}}}